Sabzevari Helen 4

What Happened
Helen Sabzevari, President and CEO of Precigen (PGEN), exercised 346,836 option-derived shares and immediately sold those 346,836 shares in the open market. The exercise reported a cost basis of $2.33 per share (total $808,128). The shares were sold at a weighted-average price of $5.89 per share for total gross proceeds of $2,042,864, yielding roughly $1,234,736 before taxes and fees.

Key Details

• Transaction date: 2026-06-29; Form 4 filed 2026-07-01 (appears timely within the SEC reporting window).
• Exercise: 346,836 shares at $2.33 (total $808,128).
• Sale: 346,836 shares sold, weighted-average price $5.89, total proceeds $2,042,864; sale prices ranged $5.75–$6.04 (footnote).
• Additional derivative entry shows a $0.00 line for the conversion/derivative disposition (reflects mechanics of the exercise as reported).
• Sale executed pursuant to a pre-established 10b5-1 plan (footnote).
• Stock options exercised were fully vested (footnote).
• Shares owned after the transaction are not provided in the supplied filing data.

Context
This is effectively a cashless exercise followed by an immediate sale under a 10b5-1 plan — a common executive liquidity action rather than an open-market buy signal. The filing is factual about amounts and mechanics; any net proceeds reported here are pre-tax and before transaction fees.